SAN FRANCISCO, CA--(Marketwired - May 21, 2015) - An Israeli biotech is hard at work on a new treatment for neurodegenerative disease that holds promise in a variety of devastating diseases and enjoys fast-track and orphan drug status in its lead indication, amyotrophic lateral sclerosis (ALS). In this interview Dr. Tony Fiorino, the U.S.-based CEO of BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), tells The Life Sciences Report how his company is winning over American investors with a revolutionary, university lab-backed cell therapy.

The Life Sciences Report: BrainStorm Cell Therapeutics Inc. utilizes autologous stem cell therapies for neurodegenerative diseases, including ALS, multiple sclerosis (MS) and Parkinson's disease. Please describe the origin of your patented treatment.

Tony Fiorino: NurOwn is the trade name of our technology platform. It emerged from the neuroscience lab of Dani Offen and Eldad Melamed at Tel Aviv University. They were trying to differentiate mesenchymal stem cells (MSCs) into cells that could be active in the treatment of neurodegenerative diseases. They succeeded in identifying culture conditions that induced the MSCs to assume the phenotype of a neuronal support cell; in fact, they were called astrocyte-like cells in the early days of the company. We now refer to them as MSC-NTF cells, which is the shorthand for MSCs that are secreting neurotrophic factors (NTFs).

TLSR: Do NurOwn cells have unique characteristics that differentiate them from other cell-based therapeutics undergoing clinical trials in the neurology space?

TF: A lot of companies and academic institutions are working with MSCs, both autologous and allogeneic. MSCs are immunomodulatory, and that definitely plays a role...

Continue reading this interview with Tony Fiorino: BrainStorm Cell Therapeutics Tackles Neurodegenerative Disease with Super Cells

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.

BrainStorm Cell Therapeutics Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Tony Fiorino had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Tony Fiorino and not of The Life Sciences Report or its officers.

Contact Information:

Carrie Beal Amaro
Phone: 707-283-0676